Trial reportBritish journal of clinical pharmacology2017
Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women.
Trial report in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 62 citations in OpenAlex.
- Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women.British journal of clinical pharmacology · 2017Trial
- Treatment with a selective androgen receptor modulator (RAD140) is linked to better cardiac function, with male-specific effects that are graded by interleukin-6.GeroScience · 2026Article
- Selective Androgen Receptor Modulators in Women: What Do We Know, and What Is Still Missing.Life (Basel, Switzerland) · 2026Review
- The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP-1 Agonists: A Literature Review.Journal of diabetes · 2025Review
- Selective androgen receptor modulators: a critical appraisal.Frontiers in endocrinology · 2025Review
- Ostarine blunts the effect of endurance training on submaximal endurance in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.European journal of clinical pharmacology · 2024Review
- Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users.Journal of xenobiotics · 2023Review
- Sarcopenia and Endocrine Ageing: Are They Related?Cureus · 2022Review
- Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles.Journal of the Endocrine Society · 2022Article
- Could Overt Diabetes Be Triggered by Abuse of Selective Androgen Receptor Modulators and Growth Hormone Secretagogues? A Case Report and Review of the Literature.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
- The "Adipo-Cerebral" Dialogue in Childhood Obesity: Focus on Growth and Puberty. Physiopathological and Nutritional Aspects.Nutrients · 2021Review
- Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.The Journal of clinical investigation · 2021Article
- The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia.Frontiers in medicine · 2021Review
- Selective androgen receptor modulators: the future of androgen therapy?Translational andrology and urology · 2020Review
- Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?International journal of endocrinology · 2020Review
- Synthesis of Aryl Propionamide Scaffold Containing a Pentafluorosulfanyl Moiety as SARMs.Molecules (Basel, Switzerland) · 2019Article
- Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.Sexual medicine reviews · 2019Review
- Wasting away: How to treat cachexia and muscle wasting in chronic disease?British journal of clinical pharmacology · 2017Article
- The long and winding road for selective androgen receptor modulators.British journal of clinical pharmacology · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimSelective androgen receptor modulators (SARMs) induce anabolic effects on muscle without the adverse effects of androgenic steroids. In this first-in-human study, we report the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of the SARM GSK2881078.
methodsIn Part A, healthy young men (n = 10) received a single dose of study drug (0 mg, 0.05 mg, 0.1 mg, 0.2 mg GSK2881078 or matching-placebo). In Part B, repeat-dose cohorts in men (n = 65) were 0.05 mg, 0.2 mg then 0.08 mg, 0.24 mg, 0.48 mg, 0.75 mg, or placebo; in women (n = 24) they were 0.24 mg, 0.35 mg, or placebo (7 days for 0.5 mg, 14 days for other doses).
resultsPK analysis showed dose-proportional increases in exposure and a long >100-h half-life. No significant effects on vital signs, electrocardiograms, cardiac telemetry or standard clinical laboratory studies were observed. A dose-response effect was observed on lowering both high-density lipoprotein and sex hormone-binding globulin. In females at 0.35 mg, differences from placebo were -0.518 (95% confidence interval: -0.703, -0.334) mmol l
conclusionsThese data demonstrate pharmacodynamic effects with acceptable tolerability and support further clinical evaluation of this SARM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.